Trials / Terminated
TerminatedNCT00782561
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Kyntra Bio · Industry
- Sex
- All
- Age
- 12 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FG-3019 | FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-06-18
- Completion
- 2009-06-18
- First posted
- 2008-10-31
- Last updated
- 2019-07-31
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00782561. Inclusion in this directory is not an endorsement.